LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) ...

BTIG raised the firm’s price target on Cartesian Therapeutics (RNAC) to $44 from $42 and keeps a Buy rating on the shares. The firm cites the ...

Fintel reports that on November 14, 2025, BTIG maintained coverage of Cartesian Therapeutics (NasdaqGM:RNAC) with a Buy ...

To get a sense of who is truly in control of Cartesian Therapeutics, Inc. (NASDAQ:RNAC), it is important to understand the ownership structure of the business. We can see that individual insiders own ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic ...

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

LONDON--(BUSINESS WIRE)--According to market research firm Technavio, the global Cartesian robots market is expected to grow at a CAGR of nearly 5% over the next few years. One of the primary reasons ...

NEW YORK, May 05, 2025--(BUSINESS WIRE)--Cartesian Growth Corporation III (the "Company") announced today the closing of its initial public offering of 27,600,000 units, including 3,600,000 units ...